Avri Havron
Direktor/Vorstandsmitglied bei Active P Ltd.
Vermögen: 260 333 $ am 30.04.2024
Profil
Avri Havron is currently a Director at Active P Ltd.
Previously, he worked as a Director at AngioB Ltd.
and as a Principal at Modigen Ltd.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2024 | 179 540 ( 0,97% ) | 260 333 $ | 30.04.2024 |
Aktive Positionen von Avri Havron
| Unternehmen | Position | Beginn |
|---|---|---|
Active P Ltd.
 Active P Ltd. Pharmaceuticals: MajorHealth Technology Active P Ltd. develops proprietary oral available peptide drugs to treat diabetes. The company was founded by Shmulik Hess, Chaim Gilon, and Amnon Hoffman on September 10, 2008 and is headquartered in Kiryat Shmona, Israel. | Direktor/Vorstandsmitglied | 03.03.2010 |
Ehemalige bekannte Positionen von Avri Havron
| Unternehmen | Position | Ende |
|---|---|---|
| Modigen Ltd. | Corporate Officer/Principal | - |
AngioB Ltd.
 AngioB Ltd. Medical SpecialtiesHealth Technology AngioB Ltd. developed treatments for ischemic heart conditions. It also developed proprietary novel pro-angiogenic drugs to treat cardiovascular diseases and peripheral ischemic disorders. The company started in-vivo experiments to evaluate the pro-angiogenic potential of its lead compound in clinical-relevant models. AngioB was founded in July 2006 and was headquartered in Kiryat Shmona, Israel | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
AngioB Ltd.
AngioB Ltd. Medical SpecialtiesHealth Technology AngioB Ltd. developed treatments for ischemic heart conditions. It also developed proprietary novel pro-angiogenic drugs to treat cardiovascular diseases and peripheral ischemic disorders. The company started in-vivo experiments to evaluate the pro-angiogenic potential of its lead compound in clinical-relevant models. AngioB was founded in July 2006 and was headquartered in Kiryat Shmona, Israel | Health Technology |
Active P Ltd.
Active P Ltd. Pharmaceuticals: MajorHealth Technology Active P Ltd. develops proprietary oral available peptide drugs to treat diabetes. The company was founded by Shmulik Hess, Chaim Gilon, and Amnon Hoffman on September 10, 2008 and is headquartered in Kiryat Shmona, Israel. | Health Technology |
| Modigen Ltd. |
